Oncopharmpod
Adjuvant Abemaciclib
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:16:32
- More information
Informações:
Synopsis
FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel. NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.
